Fewer than a tenth of people who could benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it publishes its initial recommendations on the medications.
Considering over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs.
Based on estimates, more than two billion are projected to be obese by 2030 unless action is taken.
"The latest guidance acknowledges that obesity is a long-term condition that can be managed with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major hurdles to broad availability to the jabs that can assist patients in reducing significant body mass, notes the organization.
Weight-Loss Drug Shortage
Even under the present best projected outlook, the production of these medications could only cover about 100 million people – less than 10% of those who need them, according to the health organization.
The guideline calls on countries and companies to increase availability, by approaches including voluntary licensing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Weight-Loss Jabs Work
These medications imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so people eat less.
People usually begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Studies suggests patients may see weight return within a year of discontinuing the medication, because their usual food cravings return.
To be above a healthy weight elevates your likelihood for experiencing medical conditions, including diabetes, heart disease, brain attack, and certain cancers.
Excess weight concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
